Treatment of Breast Tumors using Pulsed HIFU for Delivery and Activation of Sonosensitizers
Abstract
High intensity focused ultrasound (HIFU) has been combined with a Rose Bengal derivative (RB2) to provide a synergistic cytotoxicity requiring the presence of both ultrasonic cavitation and drug. In vitro tests have shown that a short treatment (less than 30s) of pulsed HIFU with power sufficient for cavitation destroys >95% of breast cancer cells in suspension with 15micrometers of the compound. Neither the pulsed HIFU nor the RB2 compound was found to have any impact on the viability of the cells when used alone. In vivo tests using these same cells growing as a xenograft in mice were also done. Using similar treatment parameters in vivo necessitated the use of ultrasound contrast agents to initiate cavitation. When this was done, we were able to demonstrate rapid tumor regression for combination pulsed HIFU and RB2 treatments. RB2 was delivered in large doses of 250 mg/kg i.v. without any adverse side effects. We believe it should be possible to develop this technology into an alternative safe and effective means of tumor ablation for breast cancer treatment.
Document Details
- Document Type
- Technical Report
- Publication Date
- Aug 01, 2009
- Accession Number
- ADA511276
Entities
People
- Brian E. O'neill
Organizations
- Houston Methodist Research Institute